Sugi Predict

Sugi Predict / Compounds / SCHEMBL783676

SCHEMBL783676

SCHEMBL783676

O=S(=O)(Nc1cncc(Br)c1)C1CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC22A12 Q96S37 1/20 0.45
▸ PTGS1 P23219 1/20 0.40
▸ PTGS2 P35354 1/20 0.40
▸ CYP17A1 P05093 3/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ PRMT6 Q96LA8 4/20 0.39
▸ PRMT1 Q99873 1/20 0.39
▸ PRMT8 Q9NR22 1/20 0.39
▸ SGK1 O00141 1/20 0.37
▸ BRPF1 P55201 1/20 0.37
▸ HDAC4 P56524 1/20 0.36
▸ S100A9 P06702 1/20 0.36
▸ MAP2K4 P45985 2/20 0.36
▸ SMYD3 Q9H7B4 1/20 0.35
▸ TAS1R3 Q7RTX0 1/20 0.34
▸ TAS1R1 Q7RTX1 1/20 0.34
▸ TAS1R2 Q8TE23 1/20 0.34
▸ MAP2K7 O14733 1/20 0.34
▸ ALPL P05186 1/20 0.34
▸ USP7 Q93009 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3123382 0.90 SLC22A12 (0.40) SLC22A12PTGS1PTGS2CYP17A1TDP1
SCHEMBL31011098 0.80 CTPS1 (0.44) PTGS1PTGS2CYP17A1PRMT6PRMT1
SCHEMBL24369405 0.76 CTPS1 (0.47) PTGS1PTGS2CYP17A1PRMT6PRMT1
SCHEMBL17868406 0.76 KDM4E (0.53) PTGS1PTGS2CYP17A1HDAC4ALPL
SCHEMBL24369126 0.76 PRMT6 (0.50) PTGS1PTGS2CYP17A1PRMT6PRMT1
SCHEMBL856308 0.75 PIK3CB (0.54) SLC22A12PTGS1PTGS2ALPL
SCHEMBL24197365 0.75 HTR6 (0.41) TDP1PRMT6SGK1BRPF1HDAC4
SCHEMBL18123216 0.75 OPRM1 (0.48) PTGS1PTGS2TDP1PRMT6BRPF1
SCHEMBL18824555 0.74 S100A9 (0.38) PTGS2S100A9SMYD3TAS1R3TAS1R1
SCHEMBL18197402 0.73 HSD17B1 (0.40) CYP17A1TDP1SGK1BRPF1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210214323-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. 2021-07-15 — — US disclosed
US-10995078-B2 Compounds and compositions for inhibition of FASN FORMA THERAPEUTICS, INC. (US) 2021-05-04 — — US disclosed
CN-112521369-A Compounds and compositions for inhibition of FASN 福马治疗股份有限公司 2021-03-19 — — CN disclosed
EP-3587406-B1 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER FORMA THERAPEUTICS INC (US) 2021-01-27 — — EP disclosed
CN-105492008-B Compounds and compositions for inhibition of FASN 福马治疗股份有限公司 2020-11-27 — — CN disclosed
US-20200347025-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. 2020-11-05 — — US disclosed
US-10800750-B2 Compounds and compositions for inhibition of FASN FORMA THERAPEUTICS, INC. (US) 2020-10-13 — — US disclosed
US-10472342-B2 Compounds and compositions for inhibition of FASN FORMA THERAPEUTICS, INC. (US) 2019-11-12 — — US disclosed
US-10457655-B2 Compounds and compositions for inhibition of FASN FORMA THERAPEUTICS, INC. (US) 2019-10-29 — — US disclosed
US-10450286-B2 Compounds and compositions for inhibition of FASN FORMA THERAPEUTICS, INC. (US) 2019-10-22 — — US disclosed
US-20100179144-A1 QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-07-15 — — US disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 — — US disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 — — US disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 — — US disclosed
US-20090018131-A1 QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS ADAMS NICHOLAS D 2009-01-15 — — US disclosed
US-20090018131-A1 QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS ADAMS NICHOLAS D 2009-01-15 — — US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 — — US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 — — US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 — — US disclosed
WO-2008141065-A1 QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179144-A1 QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS JAK3, PI4KA, AKT3 SLC22A12 3959/4885PTGS1 1651/4885PTGS2 2550/4885
US-20200347025-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FASN, FABP1, SCD SLC22A12 2646/4885PTGS1 789/4885PTGS2 1057/4885
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS PIP5K1A, PIK3CB, PIK3CG SLC22A12 4115/4885PTGS1 988/4885PTGS2 1398/4885
US-10472342-B2 Compounds and compositions for inhibition of FASN FASN, FABP1, SCD SLC22A12 2646/4885PTGS1 789/4885PTGS2 1057/4885
US-10450286-B2 Compounds and compositions for inhibition of FASN FASN, FABP1, SCD SLC22A12 2646/4885PTGS1 789/4885PTGS2 1057/4885
US-20210214323-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FASN, FABP1, SCD SLC22A12 2407/4885PTGS1 897/4885PTGS2 1251/4885
US-10995078-B2 Compounds and compositions for inhibition of FASN FASN, FABP1, SCD SLC22A12 2646/4885PTGS1 789/4885PTGS2 1057/4885
US-10457655-B2 Compounds and compositions for inhibition of FASN FASN, FABP1, SCD SLC22A12 2646/4885PTGS1 789/4885PTGS2 1057/4885
US-20090018131-A1 QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS JAK3, PI4KA, AKT3 SLC22A12 3959/4885PTGS1 1651/4885PTGS2 2550/4885
US-10800750-B2 Compounds and compositions for inhibition of FASN FASN, FABP1, SCD SLC22A12 2646/4885PTGS1 789/4885PTGS2 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.